Louisiana State Employees Retirement System Takes Position in Progyny, Inc. $PGNY

Louisiana State Employees Retirement System acquired a new position in Progyny, Inc. (NASDAQ:PGNY) during the first quarter, Holdings Channel.com reports. The firm acquired 35,600 shares of the company’s stock, valued at approximately $604,000.

Other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its holdings in Progyny by 1.5% in the fourth quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Progyny by 260.9% during the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after buying an additional 1,621,688 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock valued at $43,933,000 after buying an additional 545,431 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Progyny by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock valued at $50,655,000 after buying an additional 20,533 shares during the period. Finally, ArrowMark Colorado Holdings LLC boosted its stake in shares of Progyny by 2.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock worth $41,560,000 after buying an additional 39,666 shares during the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Insider Buying and Selling

In other Progyny news, EVP Allison Swartz sold 1,199 shares of the stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total transaction of $29,998.98. Following the transaction, the executive vice president directly owned 83,316 shares of the company’s stock, valued at $2,084,566.32. This trade represents a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of Progyny stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider owned 59,117 shares in the company, valued at approximately $1,512,212.86. This trade represents a 2.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 36,916 shares of company stock worth $939,875 in the last 90 days. 9.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. Weiss Ratings upgraded Progyny from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, June 26th. Canaccord Genuity Group raised shares of Progyny from a “hold” rating to a “buy” rating and raised their price objective for the stock from $19.00 to $30.00 in a research note on Tuesday, May 19th. Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Barclays boosted their target price on shares of Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Bank of America increased their price target on shares of Progyny from $29.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and an average target price of $30.09.

Progyny Trading Down 0.5%

NASDAQ PGNY opened at $30.78 on Wednesday. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 39.97, a PEG ratio of 2.73 and a beta of 1.01. The stock has a 50-day moving average of $25.10 and a 200 day moving average of $22.57. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $31.36.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.26 by $0.24. The company had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.Progyny’s quarterly revenue was down 26.4% compared to the same quarter last year. During the same period last year, the company earned $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts predict that Progyny, Inc. will post 1.07 EPS for the current fiscal year.

Progyny announced that its board has approved a stock buyback program on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to repurchase up to 10.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its shares are undervalued.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.